Ozempic can reduce metabolic risks in schizophrenia patients, multicenter study finds

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA ...

Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
The Malaysian Reserve

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction ...

Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
Medical Dialogues

Linerixibat Shows Promising Effects on Bile Acid Metabolism and Cholestatic Itch in PBC Patients: Study

Results from the GLISTEN study, the largest investigational trial of pruritus in primary biliary cholangitis (PBC), indicate ...
Healio

Rosnilimab achieves T-cell depletion, ‘clinical proof of concept’ in rheumatoid arthritis

CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...
TMCnet

FIRST PATIENT DOSED IN CITRYLL'S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL Marks the start of the second Phase IIa trial to evaluate first-in-class monoclonal antibody CIT-013 this year, following the ...

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in co ...
WahanaRiau.com

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

GLP-1 drugs have ‘little or no effect’ on risk of obesity-related cancers, study suggests

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

(CNW) Menarini Group Presents Elacestrant (ORSERDU(R)) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer ...

Presentation Title: The ADELA study: A Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA)+ Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2-Advanced Breast Cancer ...